

# Myriam Calle Rubio

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4258381/publications.pdf>

Version: 2024-02-01

123  
papers

5,133  
citations

101543

36  
h-index

95266

68  
g-index

148  
all docs

148  
docs citations

148  
times ranked

3914  
citing authors

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax, 2004, 59, 387-395.   | 5.6  | 474       |
| 2  | Guía española de la enfermedad pulmonar obstructiva crónica (GesEPOC) 2017. Tratamiento farmacológico en fase estable. Archivos De Bronconeumología, 2017, 53, 324-335.   | 0.8  | 365       |
| 3  | Guía Española de la EPOC (GesEPOC). Tratamiento farmacológico de la EPOC estable. Archivos De Bronconeumología, 2012, 48, 247-257.  | 0.8  | 238       |
| 4  | Defining the Asthma-COPD Overlap Syndrome in a COPD Cohort. Chest, 2016, 149, 45-52.  | 0.8  | 227       |
| 5  | Espirometría. Archivos De Bronconeumología, 2013, 49, 388-401.  | 0.8  | 210       |
| 6  | Benralizumab for the Prevention of COPD Exacerbations. New England Journal of Medicine, 2019, 381, 1023-1034.   | 27.0 | 180       |
| 7  | Treatment of COPD by clinical phenotypes: putting old evidence into clinical practice. European Respiratory Journal, 2013, 41, 1252-1256.   | 6.7  | 162       |
| 8  | Fenotipos clínicos de la EPOC. Identificación, definición e implicaciones para las guías de tratamiento. Archivos De Bronconeumología, 2012, 48, 86-98.   | 0.8  | 154       |
| 9  | Validation of the "Test of the Adherence to Inhalers" (TAI) for Asthma and COPD Patients. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2016, 29, 142-152.   | 1.4  | 146       |
| 10 | Guía española de la EPOC (GesEPOC). Actualización 2014. Archivos De Bronconeumología, 2014, 50, 1-16.   | 0.8  | 143       |
| 11 | Spanish Guideline for COPD (GesEPOC). Update 2014. Archivos De Bronconeumología, 2014, 50, 1-16.  | 0.8  | 130       |
| 12 | Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD. European Respiratory Journal, 2017, 50, 1701162.   | 6.7  | 122       |
| 13 | Clinical Phenotypes of COPD: Identification, Definition and Implications for Guidelines. Archivos De Bronconeumología, 2012, 48, 86-98.   | 0.8  | 105       |
| 14 | Consenso sobre el solapamiento de asma y EPOC (ACO) entre la Guía española de la EPOC (GesEPOC) y la Guía Española para el Manejo del Asma (GEMA). Archivos De Bronconeumología, 2017, 53, 443-449.                             | 0.8  | 102       |
| 15 | Differential Effect of Modified Medical Research Council Dyspnea, COPD Assessment Test, and Clinical COPD Questionnaire for Symptoms Evaluation Within the New GOLD Staging and Mortality in COPD. Chest, 2015, 148, 159-168.   | 0.8  | 96        |
| 16 | Monitoring Breathing Rate at Home Allows Early Identification of COPD Exacerbations. Chest, 2012, 142, 1524-1529.   | 0.8  | 93        |
| 17 | Algorithm for identification of asthma-COPD overlap: consensus between the Spanish COPD and asthma guidelines. European Respiratory Journal, 2017, 49, 1700068.   | 6.7  | 75        |
| 18 | A new approach to grading and treating COPD based on clinical phenotypes: summary of the Spanish COPD guidelines (GesEPOC). Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2013, 22, 117-121. | 2.3  | 70        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Physicians' Knowledge of Inhaler Devices and Inhalation Techniques Remains Poor in Spain. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2012, 25, 16-22.  | 1.4 | 66        |
| 20 | Exacerbations, Hospital Admissions and Impaired Health Status in Chronic Obstructive Pulmonary Disease. <i>Quality of Life Research</i> , 2006, 15, 471-480.   | 3.1 | 63        |
| 21 | Health literacy and health outcomes in chronic obstructive pulmonary disease. <i>Respiratory Medicine</i> , 2016, 115, 78-82.  | 2.9 | 62        |
| 22 | Factors Associated With the Control of Severe Asthma. <i>Journal of Asthma</i> , 2010, 47, 124-130.  | 1.7 | 57        |
| 23 | Distribution and Outcomes of a Phenotype-Based Approach to Guide COPD Management: Results from the CHAIN Cohort. <i>PLoS ONE</i> , 2016, 11, e0160770.   | 2.5 | 57        |
| 24 | Clinical audit of COPD in outpatient respiratory clinics in Spain: the EPOCONSUL study. <i>International Journal of COPD</i> , 2017, Volume 12, 417-426.   | 2.3 | 50        |
| 25 | Identification and distribution of COPD phenotypes in clinical practice according to Spanish COPD Guidelines: the FENEPOC study. <i>International Journal of COPD</i> , 2017, Volume 12, 2373-2383.  | 2.3 | 48        |
| 26 | Unidades de cuidados respiratorios intermedios. Definición y características. <i>Archivos De Bronconeumología</i> , 2005, 41, 505-512.   | 0.8 | 47        |
| 27 | Conocimientos de la población general sobre la enfermedad pulmonar obstructiva crónica y sus determinantes: situación actual y cambios recientes. <i>Archivos De Bronconeumología</i> , 2012, 48, 308-315.                                     | 0.8 | 45        |
| 28 | Reduction of severe exacerbations and hospitalization-derived costs in alpha-1-antitrypsin-deficient patients treated with alpha-1-antitrypsin augmentation therapy. <i>Therapeutic Advances in Respiratory Disease</i> , 2012, 6, 67-78.      | 2.6 | 44        |
| 29 | Validation of the spanish version of the asthma control questionnaire. <i>Clinical Therapeutics</i> , 2008, 30, 1918-1931.   | 2.5 | 43        |
| 30 | New GOLD classification: longitudinal data on group assignment. <i>Respiratory Research</i> , 2014, 15, 3.   | 3.6 | 42        |
| 31 | Treatment and quality of life in patients with chronic obstructive pulmonary disease. <i>Quality of Life Research</i> , 2002, 11, 329-338.   | 3.1 | 41        |
| 32 | Spanish COPD Guidelines (GesEPOC): Pharmacological Treatment of Stable COPD. <i>Archivos De Bronconeumología</i> , 2012, 48, 247-257.  | 0.8 | 41        |
| 33 | Impact of patient satisfaction with his or her inhaler on adherence and asthma control. <i>Allergy and Asthma Proceedings</i> , 2018, 39, 437-444.   | 2.2 | 39        |
| 34 | A proposal for the withdrawal of inhaled corticosteroids in the clinical practice of chronic obstructive pulmonary disease. <i>Respiratory Research</i> , 2017, 18, 198.   | 3.6 | 38        |
| 35 | Atención médica según el nivel de riesgo y su adecuación a las recomendaciones de la guía española de la enfermedad pulmonar obstructiva crónica (EPOC) (GesEPOC): Estudio EPOCONSUL. <i>Archivos De Bronconeumología</i> , 2018, 54, 270-279. | 0.8 | 38        |
| 36 | What pulmonologists think about the asthma&ndash;COPD overlap syndrome. <i>International Journal of COPD</i> , 2015, 10, 1321.   | 2.3 | 35        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Documento de consenso «Uso adecuado de los corticoides inhalados en la enfermedad pulmonar obstructiva crónica». Archivos De Bronconeumología, 2015, 51, 193-198.  | 0.8 | 35        |
| 38 | Multicentric study on the beta-blocker use and relation with exacerbations in COPD. Respiratory Medicine, 2014, 108, 737-744.  | 2.9 | 34        |
| 39 | Speed of Recovery from Acute Exacerbations of Chronic Obstructive Pulmonary Disease after Treatment with Antimicrobials. Clinical Drug Investigation, 2003, 23, 439-450.   | 2.2 | 33        |
| 40 | A Comprehensive, National Survey of Spirometry in Spain. Chest, 2013, 144, 601-609.  | 0.8 | 33        |
| 41 | The General Public's Knowledge of Chronic Obstructive Pulmonary Disease and Its Determinants: Current Situation and Recent Changes. Archivos De Bronconeumología, 2012, 48, 308-315.   | 0.8 | 31        |
| 42 | Consensus on the Asthma-COPD Overlap (ACO) Between the Spanish COPD Guidelines (GesEPOC) and the Spanish Guidelines on the Management of Asthma (GEMA). Archivos De Bronconeumología, 2017, 53, 443-449.   | 0.8 | 31        |
| 43 | Development and Preliminary Evaluation of the Effects of an mHealth Web-Based Platform (HappyAir) on Adherence to a Maintenance Program After Pulmonary Rehabilitation in Patients With Chronic Obstructive Pulmonary Disease: Randomized Controlled Trial. JMIR MHealth and UHealth, 2020, 8, e18465. | 3.7 | 31        |
| 44 | ABPA mimicking bronchogenic cancer. Allergy: European Journal of Allergy and Clinical Immunology, 2001, 56, 80-81.   | 5.7 | 30        |
| 45 | Spanish COPD Guidelines (GesEPOC) 2017. Pharmacological Treatment of Stable Chronic Obstructive Pulmonary Disease. Archivos De Bronconeumología, 2017, 53, 324-335.  | 0.8 | 30        |
| 46 | &lt;p&gt;A Proposed Approach to Chronic Airway Disease (CAD) Using Therapeutic Goals and Treatable Traits: A Look to the Future&lt;/p&gt;. International Journal of COPD, 2020, Volume 15, 2091-2100.  | 2.3 | 27        |
| 47 | [Translated article] Spanish COPD guidelines (GesEPOC) 2021: Updated pharmacological treatment of stable COPD. Archivos De Bronconeumología, 2022, 58, T69-T81.  | 0.8 | 27        |
| 48 | Effectiveness and Safety of Inhaled Antibiotics in Patients With Chronic Obstructive Pulmonary Disease. A Multicentre Observational Study. Archivos De Bronconeumología, 2022, 58, 11-21.  | 0.8 | 25        |
| 49 | The variability of respiratory symptoms and associated factors in COPD. Respiratory Medicine, 2017, 129, 165-172.  | 2.9 | 24        |
| 50 | Chronic obstructive pulmonary disease History Assessment in Spain: una valoración multidimensional de la enfermedad pulmonar obstructiva crónica. Método y organización del trabajo. Archivos De Bronconeumología, 2012, 48, 453-459.  | 0.8 | 22        |
| 51 | Características de los pacientes con EPOC tratados en neumología en España a los grupos GOLD y fenotipos clínicos GesEPOC. Archivos De Bronconeumología, 2018, 54, 559-567.  | 0.8 | 22        |
| 52 | GesEPOC 2021: un paso más en la personalización del tratamiento de la EPOC. Archivos De Bronconeumología, 2021, 57, 9-10.  | 0.8 | 21        |
| 53 | Clinical Application of the COPD Assessment Test. Chest, 2014, 146, 111-122.   | 0.8 | 20        |
| 54 | Consensus document on the diagnosis and treatment of chronic bronchial infection in chronic obstructive pulmonary disease. Archivos De Bronconeumología, 2020, 56, 651-664.  | 0.8 | 20        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Natural Course of the Diffusing Capacity of the Lungs for Carbon Monoxide in COPD. <i>Chest</i> , 2021, 160, 481-490.   | 0.8 | 16        |
| 56 | Compliance and Utility of a Smartphone App for the Detection of Exacerbations in Patients With Chronic Obstructive Pulmonary Disease: Cohort Study. <i>JMIR MHealth and UHealth</i> , 2020, 8, e15699.                  | 3.7 | 16        |
| 57 | [Translated article] Spanish COPD Guidelines (GesEPOC) 2021 Update. Diagnosis and Treatment of COPD Exacerbation Syndrome. <i>Archivos De Bronconeumologia</i> , 2022, 58, T159-T170.                                   | 0.8 | 16        |
| 58 | Cambios interregionales en la realización e interpretación de las espirometrías en España: estudio 3E. <i>Archivos De Bronconeumologia</i> , 2014, 50, 475-483.   | 0.8 | 15        |
| 59 | Asthma patient satisfaction with different dry powder inhalers. <i>Expert Review of Respiratory Medicine</i> , 2019, 13, 133-138.   | 2.5 | 15        |
| 60 | Validación externa de las recomendaciones del Consenso multidisciplinar sobre Terapia Inhalada. <i>Archivos De Bronconeumologia</i> , 2012, 48, 189-196.  | 0.8 | 14        |
| 61 | Variability in adherence to clinical practice guidelines and recommendations in COPD outpatients: a multi-level, cross-sectional analysis of the EPOCONSUL study. <i>Respiratory Research</i> , 2017, 18, 200.          | 3.6 | 14        |
| 62 | Testing for alpha-1 antitrypsin in COPD in outpatient respiratory clinics in Spain: A multilevel, cross-sectional analysis of the EPOCONSUL study. <i>PLoS ONE</i> , 2018, 13, e0198777.                                | 2.5 | 14        |
| 63 | The Importance of Reference Centers and Registries for Rare Diseases: The Example of Alpha-1 Antitrypsin Deficiency. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2020, 17, 346-354.                 | 1.6 | 14        |
| 64 | Results of a Diagnostic Procedure Based on Multiplex Technology on Dried Blood Spots and Buccal Swabs for Subjects With Suspected Alpha1 Antitrypsin Deficiency. <i>Archivos De Bronconeumologia</i> , 2021, 57, 42-50. | 0.8 | 14        |
| 65 | Determinants of medical prescriptions for COPD care: an analysis of the EPOCONSUL clinical audit. <i>International Journal of COPD</i> , 2018, Volume 13, 2279-2288.  | 2.3 | 13        |
| 66 | Spanish COPD guidelines (GesEPOC) 2021: Updated pharmacological treatment of stable COPD. <i>Archivos De Bronconeumologia</i> , 2021, 58, T69-T69.  | 0.8 | 13        |
| 67 | Oxygenation With a Single Portable Pulse-Dose Oxygen-Conserving Device and Combined Stationary and Portable Oxygen Delivery Devices in Subjects With COPD. <i>Respiratory Care</i> , 2015, 60, 382-387.                 | 1.6 | 12        |
| 68 | Medical Care According to Risk Level and Adaptation to Spanish COPD Guidelines (GesEPOC): The Epoconsul Study. <i>Archivos De Bronconeumologia</i> , 2018, 54, 270-279.   | 0.8 | 11        |
| 69 | Long-term Outcomes and Recovery of Patients who Survived COVID-19: LUNG INJURY COVID-19 Study. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac098.  | 0.9 | 11        |
| 70 | Health-Care Quality Standards in Chronic Obstructive Pulmonary Disease. <i>Archivos De Bronconeumologia</i> , 2009, 45, 196-203.  | 0.8 | 10        |
| 71 | Validación de la versión en español del cuestionario COPD-Q/EPOC-Q de conocimiento de la EPOC. <i>Archivos De Bronconeumologia</i> , 2016, 52, 12-16.   | 0.8 | 10        |
| 72 | Utility of Transient Elastography for the Screening of Liver Disease in Patients with Alpha1-Antitrypsin Deficiency. <i>Journal of Clinical Medicine</i> , 2021, 10, 1724.  | 2.4 | 10        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 73 | Inter-Regional Changes in the Performance and Interpretation of Spirometry in Spain: 3E Study. Archivos De Bronconeumologia, 2014, 50, 475-483.  | 0.8 | 9         |
| 74 | The importance of symptoms in the longitudinal variability of clusters in COPD patients: A validation study. Respirology, 2018, 23, 485-491.   | 2.3 | 9         |
| 75 | Guidelines for the Management of Respiratory Complications in Patients With Neuromuscular Disease. Archivos De Bronconeumologia, 2013, 49, 306-313.  | 0.8 | 8         |
| 76 | Differences in the use of spirometry between rural and urban primary care centers in Spain. International Journal of COPD, 2015, 10, 1633.   | 2.3 | 8         |
| 77 | [Translated article] Spanish COPD Guidelines (GesEPOC 2021): Non-pharmacological Treatment Update. Archivos De Bronconeumologia, 2022, 58, T345-T351.  | 0.8 | 8         |
| 78 | Results of a Diagnostic Procedure Based on Multiplex Technology on Dried Blood Spots and Buccal Swabs for Subjects With Suspected Alpha1 Antitrypsin Deficiency. Archivos De Bronconeumologia, 2021, 57, 42-50.                      | 0.8 | 7         |
| 79 | Conocimiento de la enfermedad pulmonar obstructiva crónica, presencia de síntomas respiratorios crónicos y uso de la espirometría en la población española: estudio CONOCEPOC 2019. Archivos De Bronconeumologia, 2021, 57, 741-749. | 0.8 | 7         |
| 80 | Changes and Clinical Consequences of Smoking Cessation in Patients With COPD. Chest, 2018, 154, 274-285.   | 0.8 | 6         |
| 81 | Knowledge of chronic obstructive pulmonary disease, presence of chronic respiratory symptoms and use of spirometry among the Spanish population: CONOCEPOC 2019 study. Archivos De Bronconeumologia, 2021, 57, 741-749.              | 0.8 | 6         |
| 82 | External Validation of the Recommendations of the Multidisciplinary Consensus About Inhaled Therapies. Archivos De Bronconeumologia, 2012, 48, 189-196.  | 0.8 | 5         |
| 83 | Determinants of use of the bronchodilator test in primary and secondary care: results of a national survey in Spain. Clinical Respiratory Journal, 2016, 10, 217-222.  | 1.6 | 5         |
| 84 | Assessing the clinical practice in specialized outpatient clinics for chronic obstructive pulmonary disease: Analysis of the EPOCONSUL clinical audit. PLoS ONE, 2019, 14, e0211732.   | 2.5 | 4         |
| 85 | [Translated article] Spanish COPD Guideline (GesEPOC) Update: Comorbidities, Self-Management and Palliative Care. Archivos De Bronconeumologia, 2022, 58, T334-T344.   | 0.8 | 4         |
| 86 | Evaluating the impact of morning symptoms in COPD using the Capacity of Daily Living during the Morning (CDLM) questionnaire. International Journal of COPD, 2018, Volume 13, 3837-3844.   | 2.3 | 3         |
| 87 | Characteristics of COPD Patients Managed in Respiratory Medicine Departments in Spain, According to GOLD Groups and GesEPOC Clinical Phenotypes. Archivos De Bronconeumologia, 2018, 54, 559-567.                                    | 0.8 | 3         |
| 88 | Prevalence of modifiable factors limiting treatment efficacy of poorly controlled asthma patients: EFIMERA observational study. Npj Primary Care Respiratory Medicine, 2020, 30, 33.   | 2.6 | 3         |
| 89 | Noninvasive electrical stimulation of oropharyngeal muscles in obstructive sleep apnea. Expert Review of Respiratory Medicine, 2021, 15, 1-14.   | 2.5 | 3         |
| 90 | Off-label use of inhaled bronchodilators in hospitalised patients in Spain: a multicentre observational study. European Journal of Hospital Pharmacy, 2021, 28, e23-e28.   | 1.1 | 3         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 91  | Spanish COPD Guidelines (GesEPOC) 2021 Update Diagnosis and Treatment of COPD Exacerbation Syndrome. Archivos De Bronconeumologia, 2021, , .                                 | 0.8 | 3         |
| 92  | Factors associated with therapeutic compliance in COPD. , 2017, , .  |     | 3         |
| 93  | Assessing the Usefulness of the Prevexair Smartphone Application in the Follow-Up High-Risk Patients with COPD. International Journal of COPD, 2021, Volume 16, 53-65.       | 2.3 | 2         |
| 94  | COPD Clinical Control: predictors and long-term follow-up of the CHAIN cohort. Respiratory Research, 2021, 22, 36.   | 3.6 | 2         |
| 95  | Consenso sobre el diagnÃ³stico, tratamiento y seguimiento de la EPOC: Grupo de trabajo EPOC Forum. Archivos De Bronconeumologia, 2021, 57, 596-599.                          | 0.8 | 2         |
| 96  | Prevalence and impact of depression on COPD. , 2017, , .   |     | 2         |
| 97  | Testing for Vitamin D in High-Risk COPD in Outpatient Clinics in Spain: A Cross-Sectional Analysis of the VITADEPOC Study. Journal of Clinical Medicine, 2022, 11, 1347.     | 2.4 | 2         |
| 98  | Determinants in the Underdiagnosis of COPD in Spainâ€”CONOCEPOC Study. Journal of Clinical Medicine, 2022, 11, 2670.   | 2.4 | 2         |
| 99  | NeumonÃ­as de lenta resoluciÃ³n. Revista Clinica Espanola, 2004, 204, 375-378.   | 0.6 | 1         |
| 100 | Bronquiectasias. Medicine, 2002, 8, 4121-4126.   | 0.0 | 0         |
| 101 | El uso de roflumilast en el tratamiento de la enfermedad pulmonar obstructiva crÃ³nica: la perspectiva del neumÃ³logo. Revista De Patologia Respiratoria, 2012, 15, 111-122. | 0.0 | 0         |
| 102 | FormaciÃ³n continuada en espirometrÃ­as: una luz en el camino. Archivos De Bronconeumologia, 2013, 49, 369-370.  | 0.8 | 0         |
| 103 | Continuing Education in Spirometry: A Light Along the Way. Archivos De Bronconeumologia, 2013, 49, 369-370.  | 0.8 | 0         |
| 104 | Quality of Spirometric Data in Spain: The 3E Study. Archivos De Bronconeumologia, 2016, 52, 109.   | 0.8 | 0         |
| 105 | Validation of the Spanish Version of the COPD-Q Questionnaire on COPD Knowledge. Archivos De Bronconeumologia, 2016, 52, 12-16.  | 0.8 | 0         |
| 106 | Calidad de los datos de las espirometrÃ­as en EspaÃ±a: estudio 3E. Archivos De Bronconeumologia, 2016, 52, 109.  | 0.8 | 0         |
| 107 | For the Patient. Allergy and Asthma Proceedings, 2018, 39, 472-472.  | 2.2 | 0         |
| 108 | Distribution of COPD phenotypes according to the Spanish COPD guidelines in clinical practice. , 2015, , .   |     | 0         |

| #   | ARTICLE   | IF | CITATIONS |
|-----|---|----|-----------|
| 109 | Home pulmonary rehabilitation program in COPD : Conditioning factors. , 2016, , .   |    | 0         |
| 110 | Control of asthma, adherence to inhaled therapy and usefulness of the Test of Adherence to Inhalers (TAI). Results of the ASCONA study. , 2017, , .                     |    | 0         |
| 111 | Impact of asthmatic patient satisfaction with the inhaler upon adherence, disease control and quality of life. Results of the ASCONA study. , 2017, , .                 |    | 0         |
| 112 | Clinical audit of COPD in outpatient respiratory clinics in Spain. Effect of specialized COPD clinics and general respiratory clinics: the EPOCONSUL study. , 2017, , . |    | 0         |
| 113 | Use of health care resources in admissions of COPD exacerbations. , 2017, , .   |    | 0         |
| 114 | Factors associated with testing of COPD patients for serum AAT levels to detect cases of AATD. The EPOCONSUL study.. , 2018, , .  |    | 0         |
| 115 | The Capacity of Daily Living during the Morning (CDLM) questionnaire: Evaluating the impact of morning symptoms in COPD. , 2018, , .                                    |    | 0         |
| 116 | Clinical control of COPD according to outpatient respiratory clinics: general versus specialized COPD. , 2019, , .  |    | 0         |
| 117 | Pro-inflammatory / anti-inflammatory capacity of lymphocyte cells in COPD. , 2019, , .  |    | 0         |
| 118 | Clinical characteristics of COPD and resources in general and specialized COPD outpatient respiratory clinics. , 2019, , .  |    | 0         |
| 119 | KaLinix® in the treatment of Obstructive Sleep Apnea-Hypopnea syndrome (OSAHS). , 2020, , .   |    | 0         |
| 120 | Are there Clinically Relevant Benefits in a Structured Program of Physical Activity in COPD? Activepoc Study. , 2020, , .   |    | 0         |
| 121 | Benefits of Measured Isotiming in Constant Cardiopulmonary Exercise Testing in a Structured Physical Activity Program. , 2020, , .                                      |    | 0         |
| 122 | Diagnostic efficacy of the KaLinix® intelligent medical device for diagnosis of obstructive sleep apnea and hypopnea syndrome. , 2020, , .                              |    | 0         |
| 123 | Important Benefits of EBUS-TBNA in Assessing PD-L1 Expression in NSCLC. , 2020, , .   |    | 0         |